SNRPF Antibody

What is SNRPF and why is it important in molecular biology research?

SNRPF is a core component of the spliceosomal U1, U2, U4, and U5 small nuclear ribonucleoproteins (snRNPs), which are essential building blocks of the spliceosome. It plays a crucial role in pre-mRNA splicing, a fundamental process in gene expression regulation. SNRPF functions in both the pre-catalytic spliceosome B complex and activated spliceosome C complexes . Additionally, it participates in the splicing of U12-type introns as a component of the minor spliceosome and contributes to histone 3'-end processing as part of the U7 snRNP . The protein has a molecular weight of approximately 10 kDa and is also known by synonyms including SMF, Sm-F, snRNP-F, and Sm protein F . Given its central role in RNA processing, SNRPF is a valuable target for investigating splicing mechanisms and related pathologies.

What types of SNRPF antibodies are available for research applications?

SNRPF antibodies are available in multiple formats to suit various research applications:

• Based on origin:

  • Polyclonal antibodies: Such as 14977-1-AP from Proteintech and A04693 from Boster Bio, produced in rabbits

  • Monoclonal antibodies: Including recombinant options like EPR10388 and EPR10389(B) from Abcam

• Based on applications:

  • Western Blot (WB)-optimized antibodies

  • IHC-compatible antibodies

  • IF/ICC-validated antibodies

  • Flow cytometry-suitable antibodies

• Based on species reactivity:
  Most commercially available SNRPF antibodies demonstrate reactivity with human, mouse, and rat samples, while some offer broader cross-reactivity with additional species .

What is the recommended protocol for Western blot analysis using SNRPF antibodies?

For optimal Western blot results with SNRPF antibodies, follow this methodological approach:

• Sample preparation:

  • Validated cell lines include: HeLa, HepG2, MCF-7, 293T, LO2, SGC-7901 cells

  • Validated tissue samples include: human heart tissue, mouse kidney/liver/brain/testis tissue

• Antibody dilution:

  • Primary antibody (SNRPF): 1:500-1:3000 dilution is typically recommended

  • Secondary antibody: HRP-conjugated anti-rabbit antibody at 1:2000 dilution

• Expected results:

  • Predicted band size: 10 kDa

  • Observed band size: 10-12 kDa depending on the specific antibody used

• Controls:

  • Positive controls: HeLa cell lysate, human heart tissue lysate

  • Negative controls: Samples known not to express SNRPF or rabbit IgG isotype control

This protocol has been validated with multiple SNRPF antibodies and consistently detects the target protein at the expected molecular weight .

How should SNRPF antibodies be used for immunohistochemical (IHC) applications?

For successful IHC staining with SNRPF antibodies, follow these methodological guidelines:

• Tissue preparation:

  • Use formalin-fixed, paraffin-embedded (FFPE) tissue sections (3 μm thickness)

  • Validated tissues include human breast cancer tissue

• Antigen retrieval options:

  • Primary method: TE buffer pH 9.0

  • Alternative method: Citrate buffer pH 6.0

• Antibody incubation:

  • Primary antibody dilution: 1:20-1:200 (typically 1:100 for optimal results)

  • Incubation conditions: Overnight at 4°C

• Detection system:

  • Horse-radish peroxidase (HRP) antibody incubation: 10 minutes at room temperature

  • Development with 3,3-diaminobenzidine (DAB)

• Counterstaining and mounting:

  • Mount with appropriate mounting medium (e.g., Vectashield)

This protocol has been successfully used to detect SNRPF expression in cancer tissues and normal tissues for comparative analyses .

What is the optimal procedure for immunofluorescence (IF/ICC) using SNRPF antibodies?

For immunofluorescence detection of SNRPF, implement the following protocol:

• Cell preparation:

  • HeLa cells are validated for SNRPF immunofluorescence

  • Fix cells with 4% paraformaldehyde (PFA)

• Antibody application:

  • Primary antibody dilution: 1:50-1:500 (optimal results often at 1:50)

  • Secondary antibody: Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L)

• Expected cellular localization:

  • SNRPF is primarily localized in the nucleus, with some cytoplasmic expression also observed

• Controls:

  • Include rabbit IgG control to establish background staining levels

This protocol enables visualization of SNRPF's subcellular distribution pattern, which is important for understanding its functional role in pre-mRNA splicing .

How can SNRPF antibodies be used in studying autoimmune diseases?

SNRPF antibodies are valuable tools for investigating autoimmune conditions, particularly those associated with ribonucleoprotein complexes. Recent research has identified anti-SNRPA as a novel serological biomarker for systemic sclerosis (SSc) . While this focuses on a related snRNP protein, the methodological approach is applicable to SNRPF studies:

• Autoantigen screening approach:

  • Phase I: Use protein arrays (e.g., HuProt arrays) to identify candidate autoantigens

  • Phase II: Validate candidates using focused arrays with larger patient cohorts

• Serum assay protocol:

  • Create subarrays on a single slide using rubber gaskets

  • Incubate with diluted patient serum (1:1000)

  • Apply detection antibodies and analyze signal intensity

• Validation by Western blot:

  • Express and purify the protein of interest (e.g., SNRPF)

  • Perform Western blot analysis with patient sera

  • Quantify signals to determine sensitivity and specificity

• Data analysis:

  • Calculate positive rates in patient and control groups

  • Determine statistical significance of differences

  • Assess diagnostic performance using AUC analysis

This methodology allows researchers to investigate SNRPF as a potential autoantigen in various autoimmune conditions, similar to how anti-SNRPA was identified as a biomarker for SSc with 11.25% sensitivity and 96.67% specificity .

What is the role of SNRPF in cancer research and how can SNRPF antibodies contribute to oncology studies?

SNRPF has emerging significance in cancer research, with several studies highlighting its potential as a prognostic biomarker. SNRPF antibodies can be employed in oncology research through these methodological approaches:

• Expression analysis in cancer tissues:

  • Perform IHC on cancer tissue microarrays using standardized protocols

  • Compare expression levels between tumor and adjacent normal tissues

  • Correlate expression with clinical parameters and survival data

• Correlation with molecular features:

  • Analyze SNRPF expression in relation to:

    • TP53 mutation status

    • Tumor grades

    • Cancer stages

• Prognostic significance assessment:

  • Conduct univariate and multivariate Cox regression analyses

  • Generate Kaplan-Meier survival curves based on SNRPF expression levels

  • Determine hazard ratios and statistical significance

How can SNRPF antibodies be used to study immune infiltration in cancer tissues?

SNRPF antibodies can facilitate investigations into the relationship between SNRPF expression and immune cell infiltration in cancer microenvironments:

• Combined IHC approach:

  • Perform sequential or dual IHC staining for SNRPF and immune cell markers

  • Quantify spatial relationships between SNRPF-expressing cells and immune infiltrates

• Correlation analysis methods:

  • Use bioinformatic tools like TIMER and "GSVA" R package

  • Analyze correlations between SNRPF expression and specific immune cell populations

  • Generate correlation heat maps and statistical analyses

Research has revealed that SNRPF expression correlates with specific immune cell infiltration patterns:

• Positive correlation with Th2 cells

• Negative correlation with Th1 cells, mast cells, and NK cells

These correlations suggest potential immunomodulatory roles for SNRPF in the tumor microenvironment, offering new avenues for investigating cancer immunobiology .

What are common challenges when using SNRPF antibodies and how can they be addressed?

When working with SNRPF antibodies, researchers may encounter several technical challenges:

• Non-specific binding in Western blot:

  • Problem: Additional bands observed beyond the expected 10 kDa

  • Solution: Optimize blocking conditions (use 5% BSA instead of milk)

  • Solution: Adjust antibody dilution (start with manufacturer's recommendation, then titrate)

  • Solution: Increase washing time and stringency

• Weak signal in IHC:

  • Problem: Insufficient detection despite proper tissue preparation

  • Solution: Compare antigen retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0)

  • Solution: Adjust antibody concentration (try 1:20-1:50 for weak signals)

  • Solution: Extend primary antibody incubation time (overnight at 4°C)

• High background in IF/ICC:

  • Problem: Non-specific fluorescence obscuring specific signals

  • Solution: Increase blocking time and agent concentration

  • Solution: Titrate antibody to optimal concentration (1:50-1:500)

  • Solution: Include proper negative controls (rabbit IgG)

• Sample-dependent variability:

  • Problem: Inconsistent results between different sample types

  • Solution: "Sample-dependent, check data in validation data gallery"

  • Solution: Validate antibody in your specific sample type before proceeding with experiments

These optimization strategies have been validated for various SNRPF antibodies and applications, ensuring more reliable and reproducible results .

What are the best storage conditions for maintaining SNRPF antibody efficacy?

Proper storage is crucial for maintaining SNRPF antibody performance over time:

• Storage temperature:

  • Long-term storage: -20°C is recommended for most antibody formulations

  • Some formulations may be stored at -80°C for extended stability

• Buffer composition:

  • Typical storage buffer: PBS with 0.02% sodium azide and 50% glycerol, pH 7.3

  • Some preparations include 0.1% BSA for additional stability

• Aliquoting recommendations:

  • For most -20°C storage, aliquoting is unnecessary

  • For frequent use, create working aliquots to avoid freeze-thaw cycles

• Stability parameters:

  • Most SNRPF antibodies are stable for one year after shipment when stored properly

  • Reconstituted proteins should be used within 3 months

• Reconstitution protocols (for lyophilized proteins):

  • Reconstitute at 0.25 μg/μl in 200 μl sterile water

  • For long-term storage, add an equal volume of glycerol

  • Centrifuge vial before opening

  • Gently pipet and wash down vial sides to ensure complete protein recovery

Following these storage guidelines will help maintain antibody performance and extend shelf life for research applications .

How does SNRPF research contribute to our understanding of splicing mechanisms?

SNRPF research provides critical insights into fundamental splicing mechanisms:

• Core spliceosome structure:

  • SNRPF is one of eight proteins forming the snRNP structural core

  • Other core proteins include B/B-prime (SNRPB), D1 (SNRPD1), D2 (SNRPD2), D3 (SNRPD3), E (SNRPE), and G (SNRPG)

  • These proteins are essential for snRNP biogenesis and function

• Mechanistic contributions:

  • Present in both pre-catalytic spliceosome B complex and activated spliceosome C complexes

  • Involved in U12-type intron splicing in the minor spliceosome

  • Participates in histone 3'-end processing as part of U7 snRNP

• Evolutionary conservation:

  • SNRPF shows high conservation across species, indicating fundamental importance

  • Human SNRPF is reactive with mouse and rat homologs in most antibody applications

Recent structural studies, including X-ray crystallography of U1-snRNP at 5 Å resolution, have advanced our understanding of how SNRPF integrates into the splicing machinery . This structural knowledge helps elucidate the mechanisms by which SNRPF contributes to RNA processing and may inform therapeutic strategies targeting splicing dysregulation.

What is the significance of SNRPF as a potential biomarker in disease contexts?

SNRPF has emerging importance as a biomarker in several disease contexts:

These findings highlight the potential of SNRPF as a biomarker for disease diagnosis, prognosis, and potentially as a therapeutic target, particularly in cancer and autoimmune conditions.

What are promising future research directions for SNRPF antibodies in molecular medicine?

Several innovative research directions are emerging for SNRPF antibodies:

• Therapeutic target validation:

  • Using SNRPF antibodies to assess the effects of splicing inhibitors in cancer models

  • Validating SNRPF as a druggable target through antibody-based studies

  • Investigating synthetic lethality approaches combining SNRPF targeting with other therapies

• Liquid biopsy applications:

  • Developing assays to detect circulating SNRPF autoantibodies as disease biomarkers

  • Transforming array-based tests to clinically adaptable methods like western blot

  • Creating multiplex assays combining SNRPF with other biomarkers to improve diagnostic accuracy

• Immunotherapy connections:

  • Exploring the mechanistic links between SNRPF expression and immune cell infiltration

  • Investigating how SNRPF might influence response to immunotherapy

  • Developing combination approaches targeting both SNRPF and immune checkpoints

• Single-cell applications:

  • Applying SNRPF antibodies in single-cell proteomics to understand cellular heterogeneity

  • Combining with RNA-seq to correlate SNRPF protein levels with splicing patterns

  • Spatial transcriptomics integration to map SNRPF expression in tissue architecture